Rationale and Design of a Prospective, Multicenter, Observational Study Evaluating Iron Deficiency in Patients Hospitalized for Heart Failure (FERIC-RO)

Introduction: Several landmark studies, which enrolled heart failure (HF) patients who were ambulatory at the time of inclusion, identified iron deficiency (ID) as an important therapeutic target: intravenous iron administration with ferric carboxymaltose (FCM) improves morbidity, exercise capacity,...

Full description

Bibliographic Details
Main Authors: Antohi Elena Laura, Chitoiu Gabriel Tatu, Ambrosy Andrew P, Coman Ioan M, Vinereanu Dragos, Collins Sean P, Sinescu Crina, Mihaileanu Serban, Pang Peter S, Butler Javed, Chioncel Ovidiu
Format: Article
Language:English
Published: Sciendo 2018-07-01
Series:Romanian Journal of Laboratory Medicine
Subjects:
Online Access:https://doi.org/10.2478/rrlm-2018-0022
Description
Summary:Introduction: Several landmark studies, which enrolled heart failure (HF) patients who were ambulatory at the time of inclusion, identified iron deficiency (ID) as an important therapeutic target: intravenous iron administration with ferric carboxymaltose (FCM) improves morbidity, exercise capacity, and quality of life in patients with HF and reduced EF (HFrEF). However, there is still limited knowledge about ID prevalence during hospitalization for Worsening Chronic HF (WCHF) and about the relationship between ID during hospitalization and post-discharge outcomes. Although previous studies documented ID as an independent risk factor for poor outcomes in HFrEF, its prognostic significance in HF patients with EF>40% remains unclear.
ISSN:2284-5623